Software Tool for Brain Connectivity Analysis

Structural magnetic resonance imaging (MRI) is a constitutive part of the clinical assessment
of neurodegenerative patients. The routine neuroimaging evaluation of structural markers
from preclinical to conspicuous stage is a key figure of how the disease is conceptualized, and
will determine its imminent diagnosis and treatment to dementia. Atrophy, a late feature in
the progression of the disease, is now a valid diagnostic marker to the neurodegenerative
diseases. At the mild cognitive impairment stage of the Alzheimer disease (AD), the valid
diagnostic marker is the atrophy of medical temporal structure [33]. In temporal lobe epilepsy
(TLE), the atrophy of the subcortical brain structures specifically the size of the hippocampus
is observed [34]. Apart from these neurodegenerative diseases, there is a significant evidence
showing that the long-term ‘Ketum’ drug abuse also causes dementia which are profound
impairments of learning and memory. These cognitive-impairing effects are revealed by the
analysis of electroencephalogram (EEG) that shows a significant decline of delta power in the
hippocampus [35]. Additionally, in the electrocorticography (ECoG) of the frontal cortex, it
is found out that there is a complete suppression of the delta and theta bands [35].